Navigation Links
Activating protein enhances average lifespan, limits age-related disease in mice
Date:12/4/2007

St. Louis, Dec. 5, 2007 Metabolism researchers at Washington University School of Medicine in St. Louis have found that although it does not extend maximum lifespan in mice, activating a protein in muscle tissue increases average lifespan and prevents some age-related diseases. The researchers believe a similar approach may someday help people avoid age-related problems such as atherosclerosis, diabetes, hypertension and even some cancers.

In a series of experiments, the research team bred large numbers of mice, fed them a normal chow diet and followed each mouse until its natural death. Half were genetically engineered to make more of a protein in their muscle tissue called uncoupling protein-1. Their littermates did not make excess uncoupling protein. In muscle tissue, uncoupling protein-1 converts the energy from food into heat and mimics the effects of exercise.

Past research conducted in the laboratory of Clay F. Semenkovich, M.D., the Herbert S. Gasser Professor and chief of the Division of Endocrinology, Metabolism and Lipid Research, had found that mice with extra uncoupling protein-1 in muscle tissue are protected from diabetes and obesity.

Because the experiments took so long for this study and involved the breeding and following of so many mice, Semenkovich was joined on the paper by three first authors: Alison C. Gates, Ph.D., a former postdoctoral fellow in the lab now studying at Southern Illinois University Edwardsville; Carlos Bernal-Mazrachi, M.D., assistant professor of medicine and of cell biology and physiology; and Sharon L. Chinault, Ph.D., former postdoctoral fellow and now assistant professor of biology at MacMurray College in Illinois. The findings are published in the December issue of the journal Cell Metabolism.

"Uncoupling basically means generating inefficient metabolism," says Semenkovich. "We knew years ago that when mice manufactured uncoupling protein in muscle, they didn't become obese. Th
'/>"/>

Contact: Jim Dryden
jdryden@wustl.edu
314-286-0110
Washington University School of Medicine
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Cancer drug works by overactivating cancer gene
2. Draining away brains toxic protein to stop Alzheimers
3. Penn study finds pro-death proteins required to regulate healthy immune function
4. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
5. Emory researchers identify signaling protein for multiple myeloma
6. Human C-reactive protein regulates myeloma tumor cell growth and survival
7. Lowering Blood Protein Wont Help Kidney Patients
8. Blood protein detects lung cancer, even at earliest stage
9. Natural Protein Could Help Spot, Treat Liver Cancer
10. Heat shock proteins are co-opted for cancer
11. How adhesive protein causes malaria
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10BioCryst Provides Update Regarding Peramivir for Influenza 5116 1BioCryst Provides Update Regarding Peramivir for Influenza 5116 2BioCryst Provides Update Regarding Peramivir for Influenza 5116 3BioCryst Provides Update Regarding Peramivir for Influenza 5116 4BioCryst Provides Update Regarding Peramivir for Influenza 5116 5Study explores how life experiences contribute to the biological changes of Alzheimers 10197 1Study explores how life experiences contribute to the biological changes of Alzheimers 10197 2Study explores how life experiences contribute to the biological changes of Alzheimers 10197 3Doctor Visits Are Getting Short Shrift in Tight Economy 58589 1Doctor Visits Are Getting Short Shrift in Tight Economy 58589 2